
Marcelo Vailati Negrao, MD, discusse safety outcomes with first-line olomorasib plus chemoimmunotherapy in LOXO-RAS-20001 and SUNRAY-01.

Marcelo Vailati Negrao, MD, discusse safety outcomes with first-line olomorasib plus chemoimmunotherapy in LOXO-RAS-20001 and SUNRAY-01.

John Bridgewater, BA, MBBS, MRCP, PhD, discusses the potential impact of the phase 3 HARMONi-GI1 trial on treating advanced biliary tract cancer.

Jacob Sands, MD, discusses the top findings from the phase 3 DeLLphi-305 study evaluating tarlatamab and durvalumab as first-line maintenance in SCLC.

Danny Rischin, MD, on C-POST trial findings on prognostic value of ctDNA and DFS with adjuvant cemiplimab in high-risk CSCC.

Johanna S. Enke, MD, discusses safety findings from the Re-LuPSMA trial of lutetium Lu-177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.

Rahul Winayak, MD, explains new mRCC targets—GPR65, HPK1, ENPP3, CD70—that aim to overcome immunotherapy resistance.

Darren Feldman, MD, discusses phase 1 data showing ixotatug vedotin drives notable responses in heavily pretreated germ cell tumors, with manageable ADC safety and potential phase 2 plans.

Shannon Westin, MD, MPH, weighs in on B7-H4 ADCs in gynecologic cancers, focusing on testing, toxicity in maintenance use, and sequencing amid resistance, target shifts, and expanding options.

Hannah Naughton, MD, explains how de-escalating surgery and chemotherapy in breast cancer expands breast conservation and improves quality of life.

Sherry Shen, MD, explains why invasive lobular breast cancer needs histology-specific clinical trials and how its unique biology shapes care.

Matthew Gubens, MD, MS, explains how PD-L1 expression, disease burden, and co-mutations guide first-line immunotherapy selection in metastatic non–small cell lung cancer.

At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.

Ryan Moore, MD, discusses the choice between surgery and total neoadjuvant therapy for rectal cancer and when watch-and-wait is feasible.

Four oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.

J. Thaddeus Beck, MD, discusses clinic logistics, patient preferences, and the future of on-body applicators as oncology shifts from intravenous to subcutaneous delivery.

Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.

Rethink trial design with decentralized, community-based models to cut barriers, let patients enroll closer to home, and preserve high-quality safety data.

J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.

Ashley Rosko, MD, discusses how telehealth can improve access to myeloma transplant evaluation, reduce care disparities, and address implementation barriers.

Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.

In this episode of The OncoloGIST, myeloma experts discuss the abstracts they most anticipated at IMS 2026, including EXCALIBER-RRMM and PERSEUS.

Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.

Al-Ola Abdallah, MD, discusses IMiD-based holding therapy before leukapheresis and its safety in patients with myeloma receiving CAR T-cell therapy.

Explore why some patients with multiple myeloma miss stem cell transplant, spotlighting age, race and socioeconomic barriers, plus community–tertiary partnerships to expand access.

Paula Rodriguez-Otero, MD, discusses how T-cell–engaging therapies are aiming to meaningfully impact or negate the disease course of high-risk smoldering myeloma.

Learn how community oncologists expand clinical trial access, strengthen safety monitoring, and offer patients nearby investigational therapies and more treatment options.

Bispecific antibodies, CAR T therapy, and targeted drugs transform non-Hodgkin lymphoma care, with earlier use and MRD-guided strategies poised to boost outcomes.

Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.

Theodore Wagener, PhD, discusses psychedelics beyond depression in cancer, including neuropathy and chemo brain, and why he expects cancer centers to adopt them.

Theodore Wagener, PhD, discusses an Ohio State feasibility study testing psilocybin-assisted therapy for depression in patients with non–small cell lung cancer.